Drug Patent Watch
NOVEMBER 19, 2021
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Slovakia. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Slovakia? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
NOVEMBER 16, 2021
In Consolidation and Preferred Pharmacy Networks in 2022’s Medicare Part D Plans , I highlighted how those networks have hijacked the world of stand-alone Medicare Part D prescription drug plans (PDP) and become a major presence in Medicare Advantage prescription drug (MA-PD) plans. Today, I examine the largest retail chains’ participation in the 21 major 2022 Part D preferred networks that the eight largest plan sponsors will offer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
NOVEMBER 19, 2021
Pfizer moment blazoned an agreement with theU.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral seeker, PAXLOVID ™ (PF-07321332; ritonavir), subject to nonsupervisory authorization from theU.S. Food and Drug Administration (FDA). Still, PAXLOVID, which began in Pfizer’s laboratories, If approved or authorized.
ProRelix Research
NOVEMBER 17, 2021
Covid 19 Booster Dose – Should we consider it? The idea of booster doses for Covid-19 vaccinations is gaining traction around the world, but India remains a skeptic. Various countries, […]. The post Covid 19 Booster Dose – Should we consider it? appeared first on ProRelix Research.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Patent Watch
NOVEMBER 14, 2021
Annual Drug Patent Expirations for AMTURNIDE Amturnide is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug. This drug has one…. The post New patent expiration for Novartis drug AMTURNIDE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
NOVEMBER 19, 2021
Today’s guest post comes from Carolyn Zele, Senior Manager of Solution Enablement at MMIT. Carolyn describes how oncology pathways were developed to help standardize treatment and ensure quality care. She argues, however, that these pathways often shut manufacturers out of the market. Click here to learn more about MMIT's Pulse Analytics solution , which provides insight into payer- and pathway-driven barriers to access.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
NIH Director's Blog: Drug Development
NOVEMBER 16, 2021
Credit: Fizkes/Shutterstock Over the course of this pandemic, significant progress has been made in treating COVID-19 and helping to save lives. That progress includes the development of life-preserving monoclonal antibody infusions and repurposing existing drugs , to which NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV ) public-private partnership has made a major contribution.
Drug Patent Watch
NOVEMBER 14, 2021
This chart shows the pharmaceutical companies with the most suppository dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most suppository dosed drugs…. The post Which pharmaceutical companies have the most suppository dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
NOVEMBER 18, 2021
In my previous post , I highlighted the largest pharmacy chains that will participate in the 2022 Medicare Part D prescription drug plans (PDP). Today, I examine how smaller pharmacies will participate as preferred cost sharing pharmacies via the pharmacy services administrative organizations (PSAOs) that represent them in negotiations with plans. As you will see here, the largest PSAOs are increasingly rejecting preferred networks.
The Pharma Data
NOVEMBER 18, 2021
— Gilead Exercises Options to Arcus’s Anti-TIGIT Program (Domvanalimab and AB308), Etrumadenant (A2a/A2b Adenosine Receptor Antagonist) and Quemliclustat (Small Molecule CD73 Inhibitor) — — Arcus to Receive Option Payments Totaling $725 million — Gilead Lores,Inc. (Nasdaq GILD) and Arcus Biosciences,Inc. (NYSE RCUS) moment blazoned that Gilead has exercised its options to three programs in Arcus’s clinical- stage portfolio, including bothanti-TIGIT motes, domvanalimab and
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Plenge Gen
NOVEMBER 15, 2021
[Disclaimers: I am an employee of Bristol Myers Squibb. The views expressed here are my own. Also, I am not a particularly good poker or chess player. It is one reason I am a popular invited guest to poker nights with friends.] I posted on poll on Twitter to ask the question is drug discovery more like poker or chess. There were over 300 responses, with the results split nearly equally (54% poker, 46% chess).
Drug Patent Watch
NOVEMBER 19, 2021
Annual Drug Patent Expirations for RAYALDEE Rayaldee is a drug marketed by Eirgen and is included in one NDA. It is available from one supplier. There are thirteen patents protecting…. The post New patent for Eirgen drug RAYALDEE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
NOVEMBER 15, 2021
Dr. Adam J. Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new live video webinar: Drug Channels Outlook 2022. Broadcast live on December 17, 2021. 12:00 p.m. to 1:30 p.m. ET This page describes the event and explains how to purchase a registration. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series.
The Pharma Data
NOVEMBER 18, 2021
Altay Therapeutics, RADD Pharmaceuticals, Rubik Therapeutics, VastBiome and Waypoint Bio to receive free year of lab bench use and other amenities at prominent bioscience incubators. Bristol Myers Squibb Company (NYSEBMY) moment blazoned five innovative biotech startups as winners of the company’s 2021 Golden Ticket Contests. The winners are RADD Pharmaceuticals and Rubik Rectifiers (LabCentral, Cambridge, MA), Waypoint Bio (BioLabs@NYULangone, New York, NY) and Altay Rectifiers and VastBiome (
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Creative Biolabs
NOVEMBER 14, 2021
Vascular dysfunction contributes to the pro-oncogenic tumor microenvironment and impedes the delivery of therapeutic drugs, so normalizing tumor blood vessels may become a potential path. Scientists have developed a new type of therapeutic antibody that may dredge and normalize blood vessels in cancerous tumors, thus providing a more effective drug delivery pathway for targeted cancer treatments, according to a study published on bioRxiv.
Drug Patent Watch
NOVEMBER 19, 2021
Annual Drug Patent Expirations for REZUROCK Rezurock is a drug marketed by Kadmon Pharms Llc and is included in one NDA. The generic ingredient in REZUROCK is belumosudil mesylate. Additional…. The post New patent for Kadmon Pharms drug REZUROCK appeared first on DrugPatentWatch - Make Better Decisions.
Eye on FDA
NOVEMBER 18, 2021
In what has been a glacially paced nomination process, the Biden Administration announced on November 12 that it would, in fact, be nominating Dr. Robert Califf to return to his role as FDA Commissioner. Acting Comissioner Janet Woodcock indicated in a tweet that she would be remaining in the role of Acting Commissioner during the confirmation process.
The Pharma Data
NOVEMBER 18, 2021
Combined efforts will work to build robust disease models while preserving privacy of large data sets from various research institutions and hospitals Collaboration to focus on four types of cancer. Sanofi blazoned moment an equity investment of$ 180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer, with a total payment of$ 90 million for three times plus fresh exploration corner- grounded payments.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
NOVEMBER 18, 2021
This chart shows the pharmaceutical companies with the most patents in Singapore. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Singapore? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
NOVEMBER 18, 2021
Annual Drug Patent Expirations for TYKERB Tykerb is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are two patents protecting…. The post New patent expiration for Novartis drug TYKERB appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
NOVEMBER 18, 2021
Data demonstrate potential of Blenrep (belantamab mafodotin-blmf) in combination with standard of care therapies in patients with newly diagnosed and relapsed/refractory multiple myeloma. GlaxoSmithKline plc moment blazoned 11 objectifications on Blenrep (belantamab mafodotin-blmf) will be presented at the forthcoming American Society of Hematology (ASH) Annual Meeting and Exposition, to be hosted in Atlanta, Georgia, US and nearly from 11-14 December 2021.
The Pharma Data
NOVEMBER 18, 2021
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic COVID-19, with no severe disease or deaths with AZD7442. Separate treatment trial showed 88% reduced risk of severe COVID-19 or death when treated within three days of symptom onset. New data from the AZD7442 COVID-19 PROVENT forestallment and Paraphernalia inpatient treatment Phase III trials both showed robust efficacity from a one- time intramuscular (IM) cure of the long- amusement antibody (LAAB) combination.
The Pharma Data
NOVEMBER 17, 2021
Approval for the first targeted treatment for eosinophilic granulomatosis with polyangiitis and the first anti-IL-5 biologic treatment for patients with hypereosinophilic syndrome or chronic rhinosinusitis with nasal polyps in Europe Mepolizumab is now the only treatment approved in Europe for use in four eosinophil-driven diseases. GlaxoSmithKline (GSK) plc moment blazoned that the European Commission has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), fo
The Pharma Data
NOVEMBER 17, 2021
Agreement builds on Pfizer’s comprehensive strategy to work toward equitable access to COVID-19 vaccines and treatments for all people, particularly those living in the poorest parts of the world Agreement will enable qualified sub-licensees to supply countries comprising approximately 53% of the world’s population Interim data from the Phase 2/3 EPIC-HR study demonstrated an 89% reduction in risk of COVID-19-related hospitalization or death compared to placebo in non-hospitalized high-risk adul
The Pharma Data
NOVEMBER 17, 2021
If approved or authorized, PAXLOVID™ (PF-07321332; ritonavir) would be the first oral antiviral of its kind, a 3CL protease inhibitor specifically designed to combat SARS-CoV-2 EUA submission includes clinical data from an interim analysis of the Phase 2/3 EPIC-HR study, which demonstrated an 89% reduction in risk of COVID-19-related hospitalization or death compared to placebo in non-hospitalized high-risk adults with COVID-19 Rolling submissions have commenced in several countries including in
The Pharma Data
NOVEMBER 17, 2021
Pfizer moment blazoned that Frank D’Amelio will retire from his position as Chief Financial Officer and Executive Vice President of Global Supply at Pfizer after a nearly 15 time distinguished career with the Company. Pfizer has initiated an external hunt for a new Chief Financial Officer and D’Amelio has agreed to stay on board through this process and serve in a consulting part through the transition.
The Pharma Data
NOVEMBER 17, 2021
Acquisition enhances Pfizer’s Oncology portfolio with addition of coming- generation, investigational immuno- rectifiers for hematological malice. Pfizer moment blazoned the successful completion of its accession of Trillium Rectifiers, a clinical stage immuno-oncology company developing innovative curatives for the treatment of cancer. As Trillium becomes part of Pfizer, it brings an emotional portfolio that includes biologics that are designed to enhance the capability of cases’ ingrain vulner
The Pharma Data
NOVEMBER 17, 2021
Mount Sinai researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for never-before-defined subtypes of a blood cancer called multiple myeloma. They also identified potential targeted treatments based on the findings, as reported in Science Advances in November.
The Pharma Data
NOVEMBER 17, 2021
For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day, hundreds of thousands of new COVID-19 cases and thousands of new deaths are still being reported worldwide, creating a need for drugs that can combat the disease caused by SARS-CoV-2.
The Pharma Data
NOVEMBER 17, 2021
VUMERITY is a next-generation oral fumarate treatment for people with relapsing-remitting MS with established efficacy and well-characterized safety, building on Biogen’s leadership in MS oral therapies Phase 3 data have demonstrated that treatment with VUMERITY results in low discontinuation rates due to its gastrointestinal (GI) tolerability profile European Union authorization follows approvals in United States, Great Britain and Switzerland, providing patients another important option as the
The Pharma Data
NOVEMBER 17, 2021
BiogenInc. and EisaiCo.,Ltd. (Tokyo, Japan) blazoned moment an update on the ongoing review of the Marketing Authorization Operation for aducanumab 100 mg/ mL concentrate result for infusion for the treatment of Alzheimer’s complaint by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Following an oral explanation held at the November meeting of the CHMP, Biogen entered a negative trend vote on the aducanumab Marketing Authorization Operation.
The Pharma Data
NOVEMBER 17, 2021
Grant to Support New Digital Programs to Reconnect Psoriatic Arthritis Patients with Healthcare Providers. Amgen (NASDAQAMGN) moment blazoned the awarding of a one- time$ entitlement to the Bath Institute of Rheumatic Conditions ( Raspberry) as part of the Understanding Psoriatic Disease Using Perceptivity for Treatment (UPLIFT) Innovation Challenge.
The Pharma Data
NOVEMBER 17, 2021
AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the last 11 months. Approximately two-thirds of these have gone to low- and lower-middle-income countries, including more than 175 million doses delivered to 130 countries through the COVAX Facility.
Expert insights. Personalized for you.
98 
Let's personalize your content